Database : MEDLINE
Search on : sneezing [Words]
References found : 3111 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 312 go to page                         

  1 / 3111 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29489694
[Au] Autor:Amraei R; Parsa A; Babaeian M
[Ad] Address:Shahid Behshti University of Medical Sciences, Tehran, Iran.
[Ti] Title:Zolpidem-induced sneezing: A case report of positive rechallenge.
[So] Source:Medicine (Baltimore);97(9):e9918, 2018 Mar.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Zolpidem, as an imidazopyridine, is a widely prescribed drug in clinical practice for short-term treatment of insomnia. Nevertheless, there have been a number of cases associated with the adverse effects of the stated drug recently. Further to the existing reports of adverse reactions to zolpidem, the current script is going to report a case in which zolpidem has induced acute repetitive sneezes. CONCLUSIONS: A high dose of zolpidem may contribute to interruption to the neurons function involved in the sneezing pathway.
[Mh] MeSH terms primary: Hypnotics and Sedatives/adverse effects
Pyridines/adverse effects
Sleep Initiation and Maintenance Disorders/drug therapy
Sneezing/drug effects
[Mh] MeSH terms secundary: Adult
Humans
Male
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Hypnotics and Sedatives); 0 (Pyridines); 7K383OQI23 (zolpidem)
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180301
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009918

  2 / 3111 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29260782
[Au] Autor:Shakhova NV; Kamaltynova EM; Lobanov YF; Ardatova TS; Nikolaeva KS
[Ad] Address:Altai State Medical University, Ministry of Health of the Russian Federation, Barnaul, Russia, 656038.
[Ti] Title:Rasprostranennost' i faktory riska allergicheskogo rinita sredi detei doshkol'nogo vozrasta. [The prevalence and risk factors of allergic rhinitis among the children of the preschool age].
[So] Source:Vestn Otorinolaringol;82(6):47-51, 2017.
[Is] ISSN:0042-4668
[Cp] Country of publication:Russia (Federation)
[La] Language:rus
[Ab] Abstract:The objective of the present work was to estimate the prevalence and risk factors of the development of allergic rhinitis among the children at the age from 3 to 6 years. The cross-sectional study was carried out in five cities of the Altai region during the period from 2015 to 2016. The prevalence of allergic rhinitis was evaluated with the use of the Russian language version of the ISAAC questionnaire filled up by the parents of the children. A child whose parents answered in the affirmative to the question 'Did your child have the runny nose, nasal congestion, and/or sneezing in the absence of cold symptoms and acute viral infection during the last 12 months?' were considered to be suffering from active allergic rhinitis (AAR). The risk factors for the development of this condition were identified with the use of an additional questionnaire. A total of 3205 filled questionnaires were available for the analysis. Based on the data obtained, the prevalence of active allergic rhinitis among the study population was estimated at 18.0% (n=577). 243 (42.1%) of these children presented with the symptoms of conjunctivitis. Therefore, the prevalence of active allergic rhinoconjunctivitis (ARC appears to be 7.5% (n=243). In fact, the medically verified diagnosis of allergic rhinitis was established only in 6.4% (n=204) children of the 577 ones having AAR. The family history of allergic rhinitis was shown to increase the risk of development of AAR by 2.6 times (OR=2.63 , 95%; CI=2.16-3.19; p<0.01) and that of ARC by 2.8 times (OR=2.85, 95%; CI=2.16-3.75; p<0.01). Masculine gender was found to increase the risk of development of both AAR an ARC by 1.3 times (OR=1.35, 95%; CI=1.01-1.37; p<0.05) and (OR=1.35, 95%; CI=1.03-1.76; p<0.05) respectively. The actual prevalence of active allergic rhinitis was significantly higher than the frequency of the medically verified diagnoses of this condition. It is concluded that the family history of allergic diseases and the masculine gender considerably increase the risk of development of both AAR and AFC.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Process
[do] DOI:10.17116/otorino201782647-51

  3 / 3111 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29337654
[Au] Autor:Liu G; Zhou X; Chen J; Liu F
[Ad] Address:1 Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, China.
[Ti] Title:Oral Antihistamines Alone vs in Combination with Leukotriene Receptor Antagonists for Allergic Rhinitis: A Meta-analysis.
[So] Source:Otolaryngol Head Neck Surg;158(3):450-458, 2018 Mar.
[Is] ISSN:1097-6817
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Objective To evaluate whether an adjuvant therapy of leukotriene receptor antagonists (LTRAs) based on oral H1-antihistamines (H1) can increase efficacy of allergic rhinitis (AR) treatment. Data Sources The search involved databases of PubMed, EMBASE, and Cochrane Central Register of Controlled Trials, from inception up to September 23, 2017. Randomized controlled trials (RCTs) that compared efficacy of LTRAs + H1 vs H1 alone were eligible. Review Methods Pooled comparative effects were measured using weighted mean difference (WMD) and 95% confidence interval (CI). Subgroup analysis comparing seasonal vs perennial AR was prespecified to explore the source of heterogeneity. The evidence quality of each outcome was assessed by the GRADE approach. Results A total of 8 RCTs were included (n = 1886), and all measured outcomes used scaled scores. Compared with H1 alone, H1 + LTRAs were superior to improve overall daytime (WMD, -0.11; 95% CI, -0.19 to -0.03, high quality) and composite (WMD, -0.12; 95% CI, -0.23 to -0.01; low quality) nasal symptoms. Specifically, H1 + LTRAs had better efficacy against composite nasal rhinorrhea, sneezing, and daytime itching but not congestion. The effects were more pronounced in patients with perennial AR compared to those with seasonal AR. There were no significant differences in nighttime nasal symptoms and eye symptoms between the 2 groups. Conclusion The current evidence suggests that LTRAs + H1 can increase the therapeutic efficacy against daytime and composite nasal symptoms, including rhinorrhea, sneezing, and itching; however, it does not affect nighttime nasal symptoms and eye symptoms. The patients with perennial AR may benefit more from the combination therapy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[St] Status:In-Data-Review
[do] DOI:10.1177/0194599817752624

  4 / 3111 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29493722
[Au] Autor:Altuntas EE; Dogan ÖT; Saraç B; Turgut NH; Durmus K; Akyol M
[Ad] Address:Department of Otolaryngology, Cumhuriyet University Faculty of Medicine, 58140 Sivas, Turkey. ealtunta@yahoo.com.
[Ti] Title:The effects of mometasone furoate and strontium chloride in a rat model of allergic rhinitis.
[So] Source:Ear Nose Throat J;97(1-2):E1-E7, 2018 Jan-Feb.
[Is] ISSN:1942-7522
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Neurogenic inflammation plays a role in the pathophysiology of allergic rhinitis. Highly effective in reducing the sensory irritation caused by some substances, strontium salts directly affect C-type nerve fibers. The aim of this study was to compare the efficacy of mometasone furoate and strontium chloride on early-phase symptoms in a rat model of allergic rhinitis. Wistar albino rats (n = 24) were randomly divided into three groups: the mometasone group, receiving 1 µg mometasone furoate (2 µl/site); the strontium 3% group, receiving 3% strontium chloride (2 µl/site); and the strontium 5% group, receiving 5% strontium chloride (2 µl/site). To induce significant nasal symptoms of allergic rhinitis, 5 µmol of histamine dihydrochloride (HDC) (2 µl/site) was administered. Symptoms of allergic rhinitis were recorded as frequencies of sneezing and nasal rubbing during a 15-minute interval. On days 1 and 2, respectively, 0.9% sodium chloride (NaCl) (2 µl/site to each nasal cavity) and HDC were administered in all of the study groups. On days 3 and 4, the study drugs were administered 10 and 30 minutes before the administration of HDC. On day 5, the study drugs were administered 10 minutes after the administration of HDC. The results of the present study revealed that when strontium chloride or mometasone furoate was administered 30 minutes before the onset of symptoms, a significant decrease was observed in sneezing and nasal rubbing. The number of sneezing occurrences was significantly lower and the number of nasal rubbing occurrences was higher in the strontium 3% group compared to the groups in which mometasone furoate and 5% strontium chloride were administered after onset of symptoms. Recent studies have investigated the efficacy and safety of strontium chloride nasal drops compared with common pharmacologic treatments of allergic rhinitis. These studies have revealed that allergic rhinitis can be successfully and safely treated with strontium-chloride-containing products, thus offering a potential new treatment strategy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[St] Status:In-Process

  5 / 3111 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29406839
[Au] Autor:Tabatabaian F; Casale TB
[Ad] Address:a Division of Allergy and Immunology, Department of Internal Medicine , Organization University of South Florida , Tampa , FL , USA.
[Ti] Title:Allergic rhinitis management: what's next?
[So] Source:Expert Rev Clin Immunol;14(3):191-196, 2018 Mar.
[Is] ISSN:1744-8409
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Allergic rhinitis (AR) is characterized by the presence of congestion, postnasal drainage, sneezing and rhinorrhea. AR contributes to reduced productivity and significant morbidity worldwide. Areas covered: We review data emphasizing that the most effective therapy to alter the course of AR is allergen-specific immunotherapy, either subcutaneous or sublingual. However, significant advancements in developing alternative forms of therapies have opened the door for potential novel avenues of treating patients with AR. We discuss novel therapies currently under investigation or recently approved, which may provide a more effective and safer treatment option. Expert commentary: Novel therapies for this common disorder which causes significant impaired quality of life are under investigation and will hopefully lead to better therapeutic options.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[St] Status:In-Data-Review
[do] DOI:10.1080/1744666X.2018.1438270

  6 / 3111 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29355679
[Au] Autor:Weinstein SF; Katial R; Jayawardena S; Pirozzi G; Staudinger H; Eckert L; Joish VN; Amin N; Maroni J; Rowe P; Graham NMH; Teper A
[Ad] Address:Allergy and Asthma Specialists Medical Group and Research Center, Huntington Beach, Calif. Electronic address: sfw@ocallergy.com.
[Ti] Title:Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma.
[So] Source:J Allergy Clin Immunol;, 2018 Jan 31.
[Is] ISSN:1097-6825
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Dupilumab, an anti-IL-4 receptor α mAb, inhibits IL-4/IL-13 signaling, key drivers of type 2/T 2 immune diseases (eg, atopic/allergic disease). In a pivotal, phase 2b study (NCT01854047), dupilumab reduced severe exacerbations, improved lung function and quality of life, and was generally well tolerated in patients with uncontrolled persistent asthma despite using medium-to-high-dose inhaled corticosteroids plus long-acting ß2-agonists. OBJECTIVE: To examine dupilumab's effect on the 22-item Sino-Nasal Outcome Test (SNOT-22) total score and its allergic rhinitis (AR)-associated items in asthma patients with comorbid perennial allergic rhinitis (PAR). METHODS: A post hoc analysis reporting data from the phase 2b study for the 200 and 300 mg every 2 week (q2w) doses under investigation in phase 3 (NCT02414854) was carried out. PAR was defined at study entry as a specific response to typical perennial antigens (IgE ≥0.35 Ku/L). RESULTS: Overall, 241 (61%) patients had PAR. In asthma patients with PAR, dupilumab 300 mg q2w versus placebo significantly improved SNOT-22 total score (least squares mean difference, -5.98; 95% CI, -10.45 to -1.51; P = .009) and all 4 AR-associated symptoms evaluated (nasal blockage, -0.60; 95% CI, -0.96 to -0.25; runny nose, -0.67; 95% CI, -1.04 to -0.31; sneezing, -0.55; 95% CI, -0.89 to -0.21; postnasal discharge, -0.49; 95% CI, -0.83 to -0.16; all P < .01). Dupilumab 200 mg q2w demonstrated numerical, but not statistically significant, decreases in SNOT-22 total score (-1.82; 95% CI, -6.46 to 2.83; P = .443 vs placebo) and in each AR-associated symptom. In patients without PAR, no differences were observed for these measures versus placebo. CONCLUSIONS: Dupilumab 300 mg q2w significantly improved AR-associated nasal symptoms in patients with uncontrolled persistent asthma and comorbid PAR.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180228
[Lr] Last revision date:180228
[St] Status:Publisher

  7 / 3111 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29471427
[Au] Autor:Cherry N; Arrandale V; Beach J; Galarneau JF; Mannette A; Rodgers L
[Ad] Address:Division of Preventive Medicine, University of Alberta, Alberta, Canada.
[Ti] Title:Health and Work in Women and Men in the Welding and Electrical Trades: How Do They Differ?
[So] Source:Ann Work Expo Health;, 2018 Feb 17.
[Is] ISSN:2398-7316
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Objectives: There is little information on how work tasks, demands, and exposures differ between women and men in nominally the same job. This is critical in setting workplace standards that will protect the health of both men and those women moving into less traditional work roles. Information used in setting standards is currently based almost entirely on male workers. This paper describes differences in work and health, and the relation between them, in women and men who have undergone the same trade training for the welding or electrical trades. Method: Four cohorts were established. Two were women across Canada in the welding and electrical trades who had been in an apprenticeship since 2005. Cohorts of men in the same trades during the same period were established in the province of Alberta, Canada. Participants completed a baseline questionnaire at recruitment and were followed up every 6 months to collect detailed information on work carried out and on their health and habits. At the end of the study (up to 5 years for women and up to 3 years for men), the cohort members completed a final questionnaire including questions on mental health, harassment, and gender. Results: The four cohorts comprised 1001 welders (447 female; 554 male) and 885 in the electrical trades (438 female; 447 male). Follow-up information was available for 89%. Women were more likely than men to have had some post-secondary education before starting their trade and were less likely to be living as married or to have a child. More welders smoked, and more men were heavy drinkers. At recruitment, more welders than those in the electrical trades reported rhinitis (sneezing and runny nose), depression, and anxiety. Female welders reported more depression (38%) than male welders (30%), compared to 24% in the electrical trades. At first follow-up, new-onset shoulder pain was more frequent in men and new-onset asthma or wheezing in welders. Within each trade, women reported less variety in tasks. Women welders were less likely to be employed in construction than men, and women were less likely to become industrial electricians. Overall, 54% of women and 46% of men reported never using respiratory protection when welding. In the end-of-study questionnaires received to date, 49% reported bullying or harassment during the apprenticeship, with higher proportions in welding than electrical trades and in women compared with men. Such harassment was reflected in higher anxiety and depression scores. Conclusions : This is the first report on these four cohorts and demonstrates the capacity for detailed analysis of the differences in exposure and new-onset occupationally related ill-health. While women and men in the same trades appear to be doing broadly similar work, and to have similar patterns on health at the first follow-up, there are some significant differences in the types of employment and variety of tasks. The very detailed information collected will allow more precise estimates of exposures to be correlated with health outcomes at the end of the follow-up period.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[St] Status:Publisher
[do] DOI:10.1093/annweh/wxy007

  8 / 3111 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29420400
[Au] Autor:Barsky M; Kelley R; Bhora FY; Hardart A
[Ad] Address:Rutgers New Jersey Medical School, New Brunswick, New Jersey; the Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia; and the Departments of Thoracic Surgery and Obstetrics and Gynecology, Mount Sinai West and Mount Sinai St Luke's, New York, New York.
[Ti] Title:Customized Pessary Fabrication Using Three-Dimensional Printing Technology.
[So] Source:Obstet Gynecol;131(3):493-497, 2018 Mar.
[Is] ISSN:1873-233X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Pessaries are a treatment option for pelvic organ prolapse, stress urinary incontinence (SUI), and cervical incompetence. An effective pessary is comfortable, corrects the presenting problem, does not cause adverse effects, and is easy to remove. Discomfort and poor fit limit the usefulness of pessaries for many women. Each patient presents with unique anatomy and thus the effectiveness of commercially available pessaries may be limited by lack of customization. METHOD: A patient presenting with SUI and failed commercial pessary fittings desired nonsurgical treatment. Using a mold fabricated with a three-dimensional printer and polylactic acid filament, a medical-grade silicone pessary was custom-made for the patient. EXPERIENCE: The silicone pessary was placed vaginally in the patient for a period of 48 hours. The patient did not report any discomfort or bladder leakage. In addition, the pessary did not dislodge with coughing, sneezing, or straining. After removal, a speculum examination showed normal epithelium. CONCLUSION: We report the successful insertion of a customized three-dimensional-printed pessary in a patient with SUI. Three-dimensional-printed pessaries are feasible and their utility may extend to the patient with anatomy incompatible with commercially available pessaries.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[St] Status:In-Data-Review
[do] DOI:10.1097/AOG.0000000000002461

  9 / 3111 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29301855
[Au] Autor:Bai Y; Liu Y; Su Z; Ma Y; Ren C; Zhao R; Ji HL
[Ad] Address:Institute of Lung and Molecular Therapy, Xinxiang Medical University, Xinxiang, China.
[Ti] Title:Gene editing as a promising approach for respiratory diseases.
[So] Source:J Med Genet;55(3):143-149, 2018 Mar.
[Is] ISSN:1468-6244
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Respiratory diseases, which are leading causes of mortality and morbidity in the world, are dysfunctions of the nasopharynx, the trachea, the bronchus, the lung and the pleural cavity. Symptoms of chronic respiratory diseases, such as cough, sneezing and difficulty breathing, may seriously affect the productivity, sleep quality and physical and mental well-being of patients, and patients with acute respiratory diseases may have difficulty breathing, anoxia and even life-threatening respiratory failure. Respiratory diseases are generally heterogeneous, with multifaceted causes including smoking, ageing, air pollution, infection and gene mutations. Clinically, a single pulmonary disease can exhibit more than one phenotype or coexist with multiple organ disorders. To correct abnormal function or repair injured respiratory tissues, one of the most promising techniques is to correct mutated genes by gene editing, as some gene mutations have been clearly demonstrated to be associated with genetic or heterogeneous respiratory diseases. Zinc finger nucleases (ZFN), transcription activator-like effector nucleases (TALEN) and clustered regulatory interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) systems are three innovative gene editing technologies developed recently. In this short review, we have summarised the structure and operating principles of the ZFNs, TALENs and CRISPR/Cas9 systems and their preclinical and clinical applications in respiratory diseases.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180223
[Lr] Last revision date:180223
[St] Status:In-Data-Review
[do] DOI:10.1136/jmedgenet-2017-104960

  10 / 3111 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29465897
[Au] Autor:Tokodi M; Csábi E; Kiricsi Á; Schultz R; Molnár H A; Rovó L; Bella Z
[Ad] Address:Szegedi Tudományegyetem, Fül-orr-gégészeti és Fej-nyaksebészeti Klinika, Szeged.
[Ti] Title:Az egyszeri allergéndózis hatása az explicit-implicit emlékezetre parlagfu-allergiás sportoló és nem sportoló betegeken. [Effects of nasal provocation with a single-dose allergen on the explicit and implicit memory of physically active and inactive patients with ragweed allergy].
[So] Source:Ideggyogy Sz;71(1-02):25-33, 2018 Jan 30.
[Is] ISSN:0019-1442
[Cp] Country of publication:Hungary
[La] Language:hun
[Ab] Abstract:Background and purpose: Allergy is an endemic disease and has a considerable impact on the quality of life. This study aimed to measure the effect of active allergic rhinitis on memory functions of physically active and inactive patients with ragweed allergy. Methods: Memory functions were assessed before and after allergen exposure. Participants in both groups were provoked nasally with 30 IR/mL ragweed allergen in each nostril. Explicit memory was measured with story-recalling and implicit memory was investigated with reaction time task. Results: In neuropsychological assessments athletes performed significantly better, compared with the control group after allergen provocation in short-term and long-term memory functions. There was no difference between the groups in the implicit tasks. Athletes have achieved better results after provocation, comparing to the baseline test and the tests that measured short-term and long-term memory functions. Conclusion: Short-term disturbing factors, e.g. swollen nasal mucosa, sneezing, and watery eyes after provocation did have not caused deterioration in cognitive functions. A single-shot allergen in high doses have caused an increase of mental concentration, which was more pronounced in athletes.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180221
[Lr] Last revision date:180221
[St] Status:In-Process
[do] DOI:10.18071/isz.71.0025


page 1 of 312 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information